2025 CSAM Annual Conference

Early Bird Holiday Sale – Save $195!

Registration for the 2025 CSAM Annual Conference online course is now open!
Listen to California’s leading addiction medicine professionals for an inspiring and educational event you won’t want to miss.

Register before December 31, 2025 to take advantage of our special Holiday Rate of $300 

Don’t wait—start the new year with new insights and renewed commitment to advancing addiction medicine.

CSAM’s Annual Conference is the West Coast’s premier Addiction Medicine conference, bringing together physicians and other healthcare professionals who specialize in the treatment of addictive disease.

This three-and-a-half-day conference offers the highest quality education sessions presented by nationally known experts within the field of addiction medicine.

Whether you’re looking to update your knowledge or add new skills to your toolbox, this conference provides opportunities for learning, networking, and collaboration among peers, colleagues, and friends.

    Earn 17.0 AMA PRA Category 1 Credits

    • Expert debates on clinical controversies
    • Advocacy strategies and policy updates
    • Trends in emerging substance use
    • Inclusive care for diverse populations
    • Advances in harm reduction practices

     

    DISCLOSURE STATEMENT

    • In accordance with CSAM and CMA policies, all planners, faculty, and moderators with control over activity content are required to disclose any financial relationships held with ineligible companies over the last 24 months. All relevant financial disclosures will be properly mitigated and disclosed at the time of the activity.

    Learning Objectives

    LEARNING OBJECTIVES

    • Apply current evidence and expert consensus to improve the diagnosis, treatment, and ongoing management of substance use disorders (SUD) in diverse populations, including incarcerated individuals, women, and people experiencing homelessness.
    • Evaluate emerging pharmacological treatments and protocols for MOUD, benzodiazepine tapering, methadone management, and alternatives like GLP-1s, Kratom, and long-acting injectables (e.g., Sublocade vs. Brixadi).
    • Enhance advocacy and policy engagement by understanding recent legislation (e.g., SB43), regulatory boundaries, and strategies for effective systems-level change in addiction medicine.
    • Integrate harm reduction strategies and compassionate overdose response techniques, including wound care for xylazine exposure and ethical considerations at end-of-life care for patients with SUD.
    • Identify and manage co-occurring issues such as gambling, anabolic steroid use, cancer risk, and sexual health concerns in patients with substance use disorders.

    Additional Information

    AttachmentSize
    PDF icon Spicy Debate on Long Acting Injectable Buprenorphine Handout395.32 KB
    PDF icon Pushing Boundaries in Addiction Medicine Handout1.25 MB
    PDF icon Improving Overdose Response Handout3.98 MB
    PDF icon Early Reflections on SB 43 Implementation Handout292.18 KB
    Course summary
    Available credit: 
    • 17.00 AMA Category 1
    Course opens: 
    11/01/2025
    Course expires: 
    12/31/2026
    Cost:
    $300.00

    PROGRAM OVERVIEW

    Welcome Message
    Dr. Jonathan Watson, CSAM Conference Chair
    Welcome to the 2025 California Society of Addiction Medicine Conference. This year’s plenary sessions bring together leaders across medicine, policy, and lived experience to explore innovative, compassionate, and evidence-based approaches to addiction treatment.

    Day One – August 14, 2025

    • Lived Experiences of Physician Advocacy: A Panel
      Tricia E. Wright, MD; Hannah Snyder, MD; Vania Rudolf, MD, MPH

    • Primary Care for People Who Use Drugs
      Trevor Lee, MD

    • Updates in Starting MOUD
      Leslie W. Suen, MD, MAS

    • Spicy Debate on Long-Acting Injectable Buprenorphine: 1st vs. 2nd Generation
      Matthew Lamon, DO; Hannah Snyder, MD

    • Protecting and Advancing the Rights of Incarcerated People
      Michelle Kotval, JD; Aaron J. Fischer, JD

    • Online Casinos, Sports Betting, and Gambling
      Tim Fong, MD; Mitika V. Kanabar, MD, MPH, DFASAM, Dip ABLM

    • Anabolic Steroids: SARMS, SERMS & Cialis
      Eric Kutscher, MD, MSc

    • Improving Overdose Response: Compassionate Care
      Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM

    • Street Smart: What’s Really in Your Drugs
      Brittany Mooney, CHW

    Day Two – August 15, 2025

    • Pushing Boundaries in Addiction Medicine
      Susan Partovi, MD; Michael E. Hoefer, MD

    • Outpatient PICC Lines: A Spicy Debate
      Tara Vijayan, MD, MPH; Amutha Rajagopal, MD, MPH, FASAM

    • Benzodiazepine-Sparing Options for Ambulatory Alcohol Detox
      Chris Blazes, MD

    • GLP-1 Agonists: A Prospective New Treatment for AUD
      Bianca M. Robertson, MD, MS; Jonathan Vargas, MD

    • Methadone Pharmacology
      Waseem Khader, DO; Tarek Haidar, MD

    • SUD in Women: Pregnancy, Incarceration, and Menopause
      Vania Rudolf, MD, MPH; Tricia E. Wright, MD; Hendree Jones, PhD

    • Early Reflections on SB 43 Implementation: A Panel Discussion
      Veronica Losso, MD; David Pating, MD; Ashley Bier

    • Kratom Use Disorder
      Isabella Morton, MD, MPH

    • Addiction Care at the End of Life
      Janet Ho, MD, MPH

    • Wound Care for People Who Use Drugs
      Rachel McFadden, MPH, BSN, RN, CEN

    • Substance Use and Cancer Risk
      Aaron Meyer, MD

    • A Practical Approach to Assessing Cannabis Use and Use Disorder
      Tauheed Zaman, MD

    Day Three – August 16, 2025

    • Upcoming Federal and California State Legislation Impacting Addiction Medicine
      Brian Furley, MD, MBA, FAPA, DFASAM

    • Sex and Substances: A Panel Discussion
      Soma Snakeoil

    • Holistic Health and Harm Reduction
      Juan Cortez, AA, Massage Therapy

    • Addiction and Primary Care for the Unhoused
      Katia Cnop, DO; Camilo Zaks, MD

    • Generative AI for the Busy Provider: Motivational Interviewing, CBT, and DBT
      Jason Satterfield, PhD

    The California Society of Addiction Medicine is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians. 

    The California Society of Addiction Medicine designates this live activity for a maximum of 17 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Available Credit

    • 17.00 AMA Category 1

    Price

    Cost:
    $300.00
    Please login or register to take this course.